Company profile GH

Guardant Health Inc
we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and n...ew products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank. Show More
Quarter analysis & expected interest

There is not enough data for Guardant Health blood test to provide analysis

Correlation between past revenue and Guardant Health blood test search interest

There is not enough data for Guardant Health blood test to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Guardant Health blood test to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Guardant Health precision oncology to provide analysis

Correlation between past revenue and Guardant Health precision oncology search interest

There is not enough data for Guardant Health precision oncology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Guardant Health precision oncology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Guardant360 test to provide analysis

Correlation between past revenue and Guardant360 test search interest

There is not enough data for Guardant360 test to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Guardant360 test to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for GuardantINFINITY test to provide analysis

Correlation between past revenue and GuardantINFINITY test search interest

There is not enough data for GuardantINFINITY test to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for GuardantINFINITY test to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for GuardantConnect software to provide analysis

Correlation between past revenue and GuardantConnect software search interest

There is not enough data for GuardantConnect software to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for GuardantConnect software to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Guardant Galaxy analytical technologies to provide analysis

Correlation between past revenue and Guardant Galaxy analytical technologies search interest

There is not enough data for Guardant Galaxy analytical technologies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Guardant Galaxy analytical technologies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for GuardantOMNI test to provide analysis

Correlation between past revenue and GuardantOMNI test search interest

There is not enough data for GuardantOMNI test to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for GuardantOMNI test to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 07:01:58.

After 39 days of this quarter the interest is at 144.0. Based on that we can calculate that during remaining 52 days it will total up to 336.0.
Guardant Reveal test expected interest is significantly higher compared to same quarter last year (+164.6%) but similar to previous quarter.

YearQ1Q2Q3Q4
20190
36
inf% QoQ
117
225.0% QoQ
49
-58.1% QoQ
2020 85
inf% YoY 73.5% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
133
171.4% YoY inf% QoQ
2021 157
84.7% YoY 18.0% QoQ
251
inf% YoY 59.9% QoQ
89
inf% YoY -64.5% QoQ
143
7.5% YoY 60.7% QoQ
2022 71
-54.8% YoY -50.3% QoQ
33
-86.9% YoY -53.5% QoQ
84
-5.6% YoY 154.5% QoQ
167
16.8% YoY 98.8% QoQ
2023 127
78.9% YoY -24.0% QoQ
24
-27.3% YoY -81.1% QoQ
134
59.5% YoY 458.3% QoQ
256
53.3% YoY 91.0% QoQ
2024 144
13.4% YoY -43.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Guardant Reveal test search interestLast update: February 09 2024 07:01:58.
Correlation coefficient between keyword and revenue is 0.31
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 07:01:59.

The average 5 years interest of Guardant Reveal test was 8.05 per week.
The last year interest of Guardant Reveal test compared to the last 5 years has changed by 39.75%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 189.95%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for GuardantINFORM research platform to provide analysis

Correlation between past revenue and GuardantINFORM research platform search interest

There is not enough data for GuardantINFORM research platform to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for GuardantINFORM research platform to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for GH
Latest articles

2026-05-12T15:07:37.000Z

TechCrunch
Exaforce raises $125M Series B to build AI for catching and stopping cyberattacks as they happen

2026-05-08T17:42:45Z

Analyst Upgrades
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $135

2026-05-08T15:17:12Z

Analyst Upgrades
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $120

2026-05-08T13:49:32Z

Analyst Upgrades
Evercore ISI Group Maintains In-Line on Guardant Health, Raises Price Target to $95

2026-05-07T20:05:00Z

BusinessWire
Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

2026-05-04T12:05:00Z

BusinessWire
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer's VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

2026-04-30T12:05:00Z

BusinessWire
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

2026-04-29T20:05:00Z

BusinessWire
Guardant Health to Participate in Upcoming Investor Conferences

2026-04-16T20:05:00Z

BusinessWire
Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-06T17:27:13Z

Analyst Upgrades
Evercore ISI Group Maintains In-Line on Guardant Health, Lowers Price Target to $90

2026-03-30T12:05:00Z

BusinessWire
Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

2026-03-24T09:15:00-04:00

PR Newswire
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

2026-03-18T12:05:00Z

BusinessWire
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

2026-03-16T12:05:00Z

BusinessWire
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

2026-03-13T12:05:00Z

BusinessWire
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare